Treat-To-Target

Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy, according to data presented at ACR Convergence 2021.

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose, according to data published in Rheumatology.

There is a lack of high-quality treatment studies in patients hospitalized for gout flares, and zero prospective studies on ways to improve urate-lowering therapy use and prevent readmission, according to data published in Rheumatology.

Although there are few studies on the subject outside of North America and Europe, the available data suggest that a minority of patients with gout receive treat-to-target care worldwide, according to data.

The last 2 decades of rheumatology management, including the treatment of rheumatoid arthritis, have been marked by improved drugs aiming at increasingly more refined therapeutic targets.

Tight control and treat-to-target, although cost-effective, are not superior to usual care for improving ASAS-HI scores in patients with axial spondyloarthritis, according to a speaker at ACR Convergence 2020.